Risk models predicting survival after reduced-intensity transplantation for myelofibrosis

被引:75
作者
Alchalby, Haefaa [1 ]
Yunus, Dinah-Rohina [1 ]
Zabelina, Tatjana [1 ]
Kobbe, Guido [2 ]
Holler, Ernst [3 ]
Bornhaeuser, Martin [4 ]
Schwerdtfeger, Rainer [5 ]
Bethge, Wolfgang [6 ]
Kvasnicka, Hans Michael [7 ]
Buesche, Guntram [8 ]
Ayuk, Francis [1 ]
Bacher, Ulrike [1 ]
Zander, Axel. R. [1 ]
Kroeger, Nicolaus [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany
[2] Univ Hosp Dusseldorf, Dept Haematol & Oncol, Dusseldorf, Germany
[3] Univ Hosp Regensburg, Dept Haematol & Oncol, Regensburg, Germany
[4] Univ Hosp Dresden, Dept Haematol & Oncol, Dresden, Germany
[5] DKD Clin, Dept Stem Cell Transplantat, Wiesbaden, Germany
[6] Univ Hosp Tubingen, Dept Haematol & Oncol, Frankfurt, Germany
[7] Goethe Univ Frankfurt, Inst Pathol, Frankfurt, Germany
[8] Hannover Med Sch, Inst Pathol, D-3000 Hannover, Germany
关键词
risk model; allogeneic stem cell transplantation; myelofibrosis; STEM-CELL TRANSPLANTATION; PROGNOSTIC SCORING SYSTEM; AGNOGENIC MYELOID METAPLASIA; SOCIETE FRANCAISE; LEUKEMIA; GREFFE; MOELLE; BLOOD;
D O I
10.1111/j.1365-2141.2011.09009.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To define a prognostic model for predicting outcome of reduced-intensity allogeneic stem cell transplantation (RIC-ASCT) for myelofibrosis we evaluated 150 homogenously treated patients and developed a new risk score for overall survival (OS). In a multivariate Cox model for OS, only JAK2 V617F wild-type, age =57 years and constitutional symptoms were independently predictive for OS (Hazard Ratio: 22 02; 2 43 and 2 80 respectively). Depending on the presence of one, two or all of these factors, HR of death was 3 08; 4 70 and 16 61 respectively ( P < 0 001). This score was compared to the Lille, Cervantes, International Prognostic Scoring System ( IPSS), dynamic IPSS ( DIPSS) and modified European Blood and Marrow Transplantation Group ( EBMT) scores. Lille score correlated significantly with OS but discriminated poorly between the intermediate and high- risk groups ( 5- year OS 56% and 51% respectively). IPSS and DIPSS correlated significantly with OS but differences between intermediate- 1 and intermediate- 2 groups were not significant ( 5- year OS 78% vs. 78% and 70%, 60% respectively). Modified EBMT and Cervantes models did not predict OS post- ASCT. In conclusion, a simple model which includes: age, JAK2 V617F- status and constitutional symptoms can clearly separate distinct risk groups and can be used in addition to the Lille model to predict OS after RIC- ASCT for myelofibrosis.
引用
收藏
页码:75 / 85
页数:11
相关论文
共 23 条
  • [1] Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
    Alchalby, Haefaa
    Badbaran, Anita
    Zabelina, Tatjana
    Kobbe, Guido
    Hahn, Joachim
    Wolff, Daniel
    Bornhaeuser, Martin
    Thiede, Christian
    Baurmann, Herrad
    Bethge, Wolfgang
    Hildebrandt, York
    Bacher, Ulrike
    Fehse, Boris
    Zander, Axel R.
    Kroeger, Nicolaus
    [J]. BLOOD, 2010, 116 (18) : 3572 - 3581
  • [2] Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
    Bacigalupo, A.
    Soraru, M.
    Dominietto, A.
    Pozzi, S.
    Geroldi, S.
    Van Lint, M. T.
    Ibatici, A.
    Raiola, A. M.
    Frassoni, F.
    De Stefano, F.
    Verdiani, S.
    Casarino, L.
    Barosi, G.
    [J]. BONE MARROW TRANSPLANTATION, 2010, 45 (03) : 458 - 463
  • [3] Outcome of Transplantation for Myelofibrosis
    Ballen, Karen K.
    Shrestha, Smriti
    Sobocinski, Kathleen A.
    Zhang, Mei-Jie
    Bashey, Asad
    Bolwell, Brian J.
    Cervantes, Francisco
    Devine, Steven M.
    Gale, Robert Peter
    Gupta, Vikas
    Hahn, Theresa E.
    Hogan, William J.
    Kroeger, Nicolaus
    Litzow, Mark R.
    Marks, David I.
    Maziarz, Richard T.
    McCarthy, Philip L.
    Schiller, Gary
    Schouten, Harry C.
    Roy, Vivek
    Wiernik, Peter H.
    Horowitz, Mary M.
    Giralt, Sergio A.
    Arora, Mukta
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (03) : 358 - 367
  • [4] Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
    Cervantes, F.
    Passamonti, F.
    Barosi, G.
    [J]. LEUKEMIA, 2008, 22 (05) : 905 - 914
  • [5] Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups
    Cervantes, F
    Barosi, G
    Demory, JL
    Reilly, J
    Guarnone, R
    Dupriez, B
    Pereira, A
    Montserrat, E
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) : 684 - 690
  • [6] New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    Cervantes, Francisco
    Dupriez, Brigitte
    Pereira, Arturo
    Passamonti, Francesco
    Reilly, John T.
    Morra, Enrica
    Vannucchi, Alessandro M.
    Mesa, Ruben A.
    Demory, Jean-Loup
    Barosi, Giovanni
    Rumi, Elisa
    Tefferi, Ayalew
    [J]. BLOOD, 2009, 113 (13) : 2895 - 2901
  • [7] Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    Deeg, HJ
    Gooley, TA
    Flowers, MED
    Sale, GE
    Slattery, JT
    Anasetti, C
    Chauncey, TR
    Doney, K
    Georges, GE
    Kiem, HP
    Martin, PJ
    Petersdorf, EW
    Radich, J
    Sanders, JE
    Sandmaier, BM
    Warren, EH
    Witherspoon, RP
    Storb, R
    Appelbaum, FR
    [J]. BLOOD, 2003, 102 (12) : 3912 - 3918
  • [8] Dupriez B, 1996, BLOOD, V88, P1013
  • [9] DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
    Gangat, Naseema
    Caramazza, Domenica
    Vaidya, Rakhee
    George, Geeta
    Begna, Kebede
    Schwager, Susan
    Van Dyke, Daniel
    Hanson, Curtis
    Wu, Wenting
    Pardanani, Animesh
    Cervantes, Francisco
    Passamonti, Francesco
    Tefferi, Ayalew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) : 392 - 397
  • [10] Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation
    Gratwohl, A
    Hermans, J
    Goldman, JM
    Arcese, W
    Carreras, E
    Devergie, A
    Frassoni, F
    Gahrton, G
    Kolb, H
    Niederwieser, D
    Ruutu, T
    Vernant, JP
    de Witte, T
    Apperley, J
    [J]. LANCET, 1998, 352 (9134) : 1087 - 1092